| 95% CrI | Probability that Etoricoxib 30 mg Shows Clinical Improvement Relative to Comparator (≥ 10 mm VAS) | |||
|---|---|---|---|---|
| Comparator (mg) | Difference in CFB* | Low | High | |
| nsNSAIDs | ||||
| naproxen 1000 | -1.3 | -6.8 | 4.1 | 0.00 |
| ibuprofen 2400 | -5.2 | -10.0 | -0.4 | 0.03 |
| diclofenac 150 | 2.0 | -3.2 | 7.1 | 0.00 |
| COX-2 selective NSAIDs | ||||
| celecoxib 200 | 0.5 | -3.2 | 4.2 | 0.00 |
| lumiracoxib 100 | -2.3 | -10.2 | 6.1 | 0.03 |
| lumiracoxib 200 | -2.5 | -10.4 | 5.9 | 0.03 |
| lumiracoxib 400 | -0.3 | -8.5 | 7.6 | 0.01 |